Browsing Schizophrenia and Psychotic Disorders by Title
Now showing items 38-57 of 126
-
Effect of point of care blood testing on physical health check completion in mental health services: mixed-methods evaluation
(2020-10)Physical health outcomes in severe mental illness are worse than in the general population. Routine physical health check completion in this group is poor. Aims To quantitatively and qualitatively evaluate the impact of ... -
Effects of SlowMo, a Blended Digital Therapy Targeting Reasoning, on Paranoia Among People With Psychosis A Randomized Clinical Trial
(2021-04)IMPORTANCE Persistent paranoia is common among patients with psychosis. Cognitive-behavioral therapy for psychosis can be effective. However, challenges in engagement and effectiveness remain. OBJECTIVE To investigate ... -
Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypy
(2023-08)Ulotaront, a trace amine-associated receptor 1 (TAAR1) and serotonin 5-HT1A receptor agonist without antagonist activity at dopamine D2 or the serotonin 5-HT2A receptors, has demonstrated efficacy in the treatment of ... -
Efficacy and Acceptability of Interventions for Attenuated Positive Psychotic Symptoms in Individuals at Clinical High Risk of Psychosis: A Network Meta-Analysis
(2018-06-12)Background: Attenuated positive psychotic symptoms represent the defining features of the clinical high-risk for psychosis (CHR-P) criteria. The effectiveness of each available treatment for reducing attenuated positive ... -
Efficacy and Effectiveness of Antipsychotics in Schizophrenia: Combining Evidence from Randomised Controlled Trials and Real-World.
(2023-10)Background: There is debate about the generalisability of results from randomised clinical trials (RCTs) to ‘real-world’ (RW) settings. Studying outcomes of treatments for schizophrenia can shed light on this issue and ... -
Efficacy of tiapride in the treatment of psychiatric disorders: A systematic review
(2022-03)Tiapride is an atypical antipsychotic used to treat alcohol withdrawal, aggressiveness and agitation, headache, dyskinesias, tic and Tourette's disorder. More recently, it has been proposed for the treatment of delirium ... -
Elevated homocysteine and N-methyl-D-aspartate-receptor antibodies as a cause of behavioural and cognitive decline in 22q11.2 deletion syndrome
(2017-12)A 19-year-old male with 22q11.2 deletion syndrome presented with a 4-year history of cognitive decline and symptoms suggestive of atypical psychosis. Potential for elevated homocysteine and NMDA-receptor antibodies in the ... -
Estimating the Economic Value of Automated Virtual Reality Cognitive Therapy for Treating Agoraphobic Avoidance in Patients With Psychosis: Findings From the gameChange Randomized Controlled Clinical Trial
(2022-11)Background: An automated virtual reality cognitive therapy (gameChange) has demonstrated its effectiveness to treat agoraphobia in patients with psychosis, especially for high or severe anxious avoidance. Its economic ... -
Evidence base for early intervention in psychosis services in rural areas: A critical review
(2020-07)Aim: Early Intervention in Psychosis teams (EITs) are a growing entity internationally, yet they remain under-researched given challenges facing their delivery. Model adaptations include stand-alone services, a hub-and-spoke ... -
Examination of the neural basis of psychotic-like experiences in adolescence during processing of emotional faces
(2020-03)Contemporary theories propose that dysregulation of emotional perception is involved in the aetiology of psychosis. 298 healthy adolescents were assessed at age 14- and 19-years using fMRI while performing a facial emotion ... -
Excessive sleepiness in patients with psychosis: An initial investigation
(2021-01)Clinical experience indicates that excessive sleepiness and hypersomnia may be a common issue for patients with psychosis. Excessive sleepiness is typically ascribed to the sedating effects of antipsychotic medications but ... -
The Experience of Sleep Problems and Their Treatment in Young People at Ultra-High Risk of Psychosis: A Thematic Analysis
(2018-08)We view sleep disruption as a contributory causal factor in the development of psychotic experiences. Clinical trials indicate that psychological interventions targeting insomnia result in improvements in both sleep and ... -
A family perspective on parental psychosis: An interpretative phenomenological analysis study
(2022-11)Objectives: While one third of people with a psychotic disorder are a parent, there has been little research to date examining the consequences of this from a whole family perspective. This study investigates families ... -
Fear of illness recurrence and mental healthanxiety in people recovering from psychosis andcommon mental health problems
(2020-06)Objectives: It is well known that mental health problems can recur even after effective treatment, leading to an understandable fear of illness recurrence (FIR) and mental health anxiety (MHA). These may themselves contribute ... -
GRIN2A (NR2A): a gene contributing to glutamatergic involvement in schizophrenia
(2023-09)Involvement of the glutamate system, particularly N-methyl-D-aspartate (NMDA) receptor hypofunction, has long been postulated to be part of the pathophysiology of schizophrenia. An important development is provided by ... -
Hebephrenia is dead, long live hebephrenia, or why Hecker and Chaslin were on to something
(2019-05-03)Since its first description in 1863, ‘hebephrenia’ has highlighted a group of patients characterised by an early onset of illness, formal thought disorder, bizarre behaviour and incongruent emotional expression. A proportion ... -
Hemizygous mutations in L1CAM in two unrelated male probands with childhood onset psychosis
(2020-06)Objective :To identify genes underlying childhood onset psychosis. Methods :Patients with onset of psychosis at age 13 or younger were identified from clinics across England, and they and their parents were exome sequenced ... -
Hippocampal Glutamate, Resting Perfusion and the Effects of Cannabidiol in Psychosis Risk
(2023-03)Background: Preclinical and human data suggest that the onset of psychosis involves hippocampal glutamatergic dysfunction, driving hyperactivity/hyperperfusion in a hippocampal-midbrain-striatal circuit. Whether glutamatergic ... -
How Efficacious Are Antipsychotic Drugs for Schizophrenia? An Interpretation Based on 13 Effect Size Indices
(2021-08)Background The magnitude of the superiority of antipsychotics over placebo is debated. One reason is that the effect-size index which is usually used in meta-analyses is in standard deviation units. Many other indices, ... -
Hummingbird Study: a study protocol for a multicentre exploratory trial to assess the acceptance and performance of a digital medicine system in adults with schizophrenia, schizoaffective disorder or first-episode psychosis
(2019-06)Introduction: In patients with schizophrenia, medication adherence is important for relapse prevention, and effective adherence monitoring is essential for treatment planning. A digital medicine system (DMS) has been ...